MOVOFLEX® Soft Chews Review 2026: What Does the Evidence Show?

Multicenter, double-blind, randomized, placebo-controlled trial · different formulation

Supplement group improved over time on CBPI pain severity, CBPI interference, LOAD, discomfort and clinical score. Placebo group also improved on CBPI interference and LOAD. Between-group difference only for CBPI pain interference (p = 0.009).

Limitations: Small sample; one of several measures separated from placebo; placebo group also improved; formula differs from the US label; owner-reported outcomes dominate; only the first 20,000 characters of the full text were available.

Species

dog

Participants / condition

52 client-owned dogs with radiographic OA, 15–35 kg, at least 3 years old; 46 completed (22 supplement, 24 placebo). Obese dogs and stifle OA excluded.

Formulation

Movoflex Soft Chews (Virbac, France): eggshell membrane 3.3%, krill meal 1.85%, Haematococcus algae meal 0.26%, hyaluronic acid 0.49%, Boswellia extract 0.57%. No vitamin D3 listed; krill is not listed on the US label.

Studied amount, not dosing advice

One soft chew daily sized for 15–35 kg dogs; milligram amounts per ingredient not reported in retrieved text.

Duration

90 days

Funding / conflicts

Financed by Virbac SA; one author is a Virbac SA employee; others received Virbac funding to conduct the study.

Multicenter, randomized, double-blind, placebo-controlled trial · ingredient

Versus placebo: CBPI function improved 20.5% at 1 week (p = 0.028) but not significantly at 6 weeks; CBPI pain 19.4% better at 1 week (p = 0.010); VCSA pain better at 6 weeks (p = 0.012); VCSA mobility and lameness not significant; CTX-II marker better at 6 weeks (p = 0.018).

Limitations: Abstract only; primary outcome missed significance at 6 weeks; different eggshell membrane brand; single ingredient, not the finished chew.

Species

dog

Participants / condition

51 dogs with suboptimal joint function at eight veterinary clinics

Formulation

NEM brand eggshell membrane alone (a different brand from the BIOVAFLEX named on this label)

Studied amount, not dosing advice

About 13.5 mg/kg (6 mg/lb) once daily

Duration

6 weeks

Funding / conflicts

Not reported in the retrieved abstract.

Prospective, randomized, double-blind, placebo-controlled trial · ingredient

HA group had higher synovial HA (p = 0.0016) and lower PON-1 (p = 0.011) versus its own baseline. No between-group differences in biomarkers. Both groups had less lameness and pain over time.

Limitations: Post-surgery population; biomarker outcomes, not flexibility; no difference from placebo reported; different product and source of hyaluronic acid.

Species

dog

Participants / condition

55 dogs, 15–45 kg, after tibial tuberosity advancement surgery for cranial cruciate ligament injury

Formulation

Mobilee rooster comb extract rich in high-molecular-weight hyaluronic acid, in soft gel capsules (27 mg HA per capsule)

Studied amount, not dosing advice

One capsule daily up to 26 kg; two capsules daily above 26 kg

Duration

10 weeks

Funding / conflicts

Bioiberica S.A.U. provided product and funding; one author is a Bioiberica employee.

Randomized controlled trial with positive control · ingredient

No differences between groups on CBPI pain interference or severity; individual improvements in some dogs on the Hudson scale in both groups.

Limitations: Very small sample; abstract only; blend cannot isolate hyaluronic acid; no placebo-only arm.

Species

dog

Participants / condition

15 working dogs with hip osteoarthritis (10 supplement, 5 carprofen)

Formulation

Commercial supplement with glucosamine HCl, chondroitin sulphate and hyaluronic acid

Studied amount, not dosing advice

Not reported in retrieved abstract

Duration

Supplement 40 days; follow-up over 5 months

Funding / conflicts

Not reported in the retrieved abstract.

Multicenter, randomized, double-blind, placebo-controlled trial · ingredient

Significant gains over placebo at 1 week for CBPI function and pain; main function measure not significant at 6 weeks; CBPI quality of life and VCSA pain better at 6 weeks.

Limitations: Abstract only; 'early stage' not defined or tested; different brand; single ingredient.

Species

dog

Participants / condition

51 dogs with suboptimal joint function

Formulation

NEM brand eggshell membrane alone

Studied amount, not dosing advice

About 13.5 mg/kg once daily

Duration

6 weeks

Funding / conflicts

Not reported in the retrieved abstract.

Open, uncontrolled multicentre clinical trial (before/after) · ingredient

Overall efficacy in 71% of 24 eligible dogs after 2 weeks; significant reductions in lameness, pain and stiff gait after 6 weeks. Brief diarrhea or flatulence in 5 dogs.

Limitations: No control group; abstract only; clinical signs, not inflammation or oxidative markers; amount far above the label's per-chew Boswellia.

Species

dog

Participants / condition

29 dogs with chronic joint and spinal disease; OA confirmed by radiography in 25

Formulation

BSB108 Boswellia serrata resin extract (Bogar AG), a different product from the label's extract

Studied amount, not dosing advice

400 mg per 10 kg body weight once daily

Duration

6 weeks

Funding / conflicts

Publication type lists non-U.S. government research support; conflicts not reported in the retrieved abstract.

Randomized, placebo-controlled, double-blind follow-up trial · ingredient

Treated group had higher blood glutathione, lower C-reactive protein and less chronic pain.

Limitations: Abstract only; mixed ingredients, so effects cannot be assigned to Boswellia; sample and statistics unavailable.

Species

dog

Participants / condition

Dogs with osteoarthritis; sample size not reported in retrieved abstract

Formulation

Supplement of Cannabis sativa oil, Boswellia serrata phytosome and ginger extract; a different product

Studied amount, not dosing advice

Not reported in retrieved abstract

Duration

3-month follow-up after 3 months of physiotherapy

Funding / conflicts

Not reported in the retrieved abstract.